Prostate Cancer Coverage from Every Angle

Bone Resorption Inhibitors: Are They of Benefit to Patients Being Treated for Metastatic Prostate Cancer?

By: Vanessa A. Carter, BS
Posted: Tuesday, September 14, 2021

According to Daniel Y.C. Heng, MD, MPH, of Tom Baker Cancer Centre, Calgary, Alberta, Canada, and colleagues, patients with metastatic castration-resistant prostate cancer harboring bone metastases may benefit from the combination of bone resorption inhibitors with abiraterone acetate and prednisone as a first-line therapy. The investigators discovered that patients who received bone resorption inhibitors such as zoledronic acid or denosumab along with first-line combination therapy experienced longer overall survival than those who did not receive these bone-strengthening agents—particular in those with high-volume disease. The results of this retrospective study were published in JAMA Network Open.

The investigators focused on 745 patients with metastatic castration-resistant prostate cancer and bone metastases who received either abiraterone acetate and prednisone alone (n = 529) or with added bone resorption inhibitors (n = 216) as first-line therapy. The median patient age was 77.6 years, and a majority of participants were White (93.8%). High-volume and low-volume disease affected 420 and 276 men, respectively.

With a median follow-up of 23.5 months, patients who received bone resorption inhibitors demonstrated a significantly longer overall survival when compared with those who did not receive them (31.8 vs. 23.0 months; P < .001). Furthermore, patients with high-volume disease given bone resorption inhibitors also had a greater overall survival benefit than patients with low-volume disease (33.6 vs. 19.7 months; P < .001).

The risk of death was decreased by 35% in the cohort given bone resorption inhibitors, although these patients were observed to develop skeletal-related-events in a shorter time than did patients given abiraterone acetate and prednisone alone (33.6 vs. 19.7 months); this risk was more than double that in patients with low-volume disease (hazard ratio [HR] = 2.29). Most notably, concomitant bone resorption inhibitors were found to be independently associated with longer overall survival (HR = 0.64, P < .001).

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.